A detailed history of Allianz Asset Management Gmb H transactions in Novavax Inc stock. As of the latest transaction made, Allianz Asset Management Gmb H holds 1,469,633 shares of NVAX stock, worth $19.1 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,469,633
Previous 634,692 131.55%
Holding current value
$19.1 Million
Previous $3.05 Million 130.6%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$3.76 - $6.02 $3.14 Million - $5.03 Million
834,941 Added 131.55%
1,469,633 $7.02 Million
Q4 2023

Feb 12, 2024

BUY
$4.8 - $7.67 $958,900 - $1.53 Million
199,771 Added 45.93%
634,692 $3.05 Million
Q3 2023

Nov 13, 2023

BUY
$6.81 - $9.74 $276,955 - $396,116
40,669 Added 10.32%
434,921 $3.15 Million
Q2 2023

Aug 11, 2023

BUY
$6.67 - $9.52 $2.63 Million - $3.75 Million
394,252 New
394,252 $2.93 Million
Q2 2022

Aug 12, 2022

SELL
$36.28 - $75.29 $1.52 Million - $3.16 Million
-41,980 Reduced 58.42%
29,882 $1.54 Million
Q1 2022

May 13, 2022

BUY
$69.73 - $142.9 $3.54 Million - $7.25 Million
50,708 Added 239.71%
71,862 $5.29 Million
Q4 2021

Feb 11, 2022

SELL
$134.56 - $217.97 $15.7 Million - $25.4 Million
-116,470 Reduced 84.63%
21,154 $3.06 Million
Q3 2021

Nov 10, 2021

BUY
$177.8 - $270.58 $15.7 Million - $23.8 Million
88,058 Added 177.66%
137,624 $28.5 Million
Q2 2021

Aug 16, 2021

SELL
$121.0 - $257.67 $3.88 Million - $8.27 Million
-32,095 Reduced 39.3%
49,566 $10.5 Million
Q1 2021

May 13, 2021

BUY
$112.98 - $319.93 $6.51 Million - $18.4 Million
57,617 Added 239.63%
81,661 $14.8 Million
Q4 2020

Feb 16, 2021

BUY
$78.74 - $139.5 $1.64 Million - $2.91 Million
20,882 Added 660.4%
24,044 $2.68 Million
Q3 2020

Nov 13, 2020

BUY
$79.44 - $178.51 $251,189 - $564,448
3,162 New
3,162 $343,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $1.01B
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track Allianz Asset Management Gmb H Portfolio

Follow Allianz Asset Management Gmb H and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

News

Stay updated on Allianz Asset Management Gmb H with notifications on news.